This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RespiGam, respiratory syncytial virus immune globulin
Description: RespiGam, Respiratory Syncytial Virus Immune Globulin Intravenous (Human) (RSV-IGIV), is a sterile liquidimmunoglobulin G containing neutralizing antibody to Respiratory Syncytial Virus (RSV).
Deal Structure: RespiGam was originally developed by MedImmune; in June 2007, AstraZeneca closed its acquisition of MedImmune.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
Partners: Pfizer Inc.
Pink Sheet In Brief: MedImmune's RespiGam
Additional information available to subscribers only: